ArticleJCI insight2017
Targeting adhesion signaling in
Open access · goldAbstract read
In one paragraph
Article in JCI insight, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- [Research Progress in Consistency of Driver Gene Status between Primary and Corresponding Metastatic Lesions in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Pooled it
- Early detection of invasive lung cancer and multiorgan metastasis by a collagen-targeted protein MRI contrast agent.Science advances · 2026Article
- mSWI/SNF complex inhibition sensitizes KRAS-mutant lung cancers to targeted therapies via epithelial-mesenchymal subversion.bioRxiv : the preprint server for biology · 2026Article
- Serine metabolism reprogramming in cancer: a multi-tiered regulatory framework.Acta biochimica et biophysica Sinica · 2025Review
- Metabolic programming defines oxygen-sensitive subpopulation hierarchies and patterning in collective invasion.Molecular biology of the cell · 2025Article
- Suppression of LKB1-mutant lung adenocarcinoma by natural killer cells from females.Journal of the National Cancer Institute · 2025Article
- High PER1 expression is associated with STK11 mutation and clinical biomarkers of immunotherapy resistance in lung adenocarcinoma.Journal of cancer research and clinical oncology · 2025Article
- Precision immune regulation in KRAS-mutated cancers: the final piece of the puzzle?Journal of experimental & clinical cancer research : CR · 2025Review
- Uncovering the rewired IAP-JAK regulatory axis as an immune-dependent vulnerability of LKB1-mutant lung cancer.Nature communications · 2025Article
- TGF-β1-mediated intercellular signaling fuels cooperative cellular invasion.Cell reports · 2025Article
- Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer.Cancer research · 2024Article
- Tenascin-C in the early lung cancer tumor microenvironment promotes progression through integrin αvβ1 and FAK.bioRxiv : the preprint server for biology · 2024Article
- Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment.Experimental hematology & oncology · 2024Article
- Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring.Frontiers in oncology · 2024Article
- Using 3-Dimensional Cultures to Propagate Genetically Modified Lung Organoids.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Serine Metabolic Reprogramming in Tumorigenesis, Tumor Immunity, and Clinical Treatment.Advances in nutrition (Bethesda, Md.) · 2023Review
- Vimentin is required for tumor progression and metastasis in a mouse model of non-small cell lung cancer.Oncogene · 2023Article
- LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer.Nature communications · 2022Article
- LKB1: Can We Target an Hidden Target? Focus on NSCLC.Frontiers in oncology · 2022Review
- Promising novel biomarkers and candidate small-molecule drugs for lung adenocarcinoma: Evidence from bioinformatics analysis of high-throughput data.Open medicine (Warsaw, Poland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 4 institutions in 2 countries.
Melissa Gilbert-RossDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Jessica KonenDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Junghui KooDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
John ShupeDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Brian S RobinsonDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine.
Walter Guy WilesWinship Cancer Institute of Emory University.
Chunzi HuangWinship Cancer Institute of Emory University.
W David MartinDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Madhusmita BeheraWinship Research Informatics Shared Resource, Winship Cancer Institute.
Geoffrey H SmithDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine.
Charles E HillDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine.
Michael R RossiDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine.
Gabriel L SicaDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine.
Manali RupjiWinship Cancer Institute of Emory University.
Zhengjia ChenWinship Cancer Institute of Emory University.
Jeanne KowalskiWinship Cancer Institute of Emory University.
Andrea L KasinskiDepartment of Biological Sciences, Purdue University, West Lafayette, Indiana, USA.
Suresh S RamalingamDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Haian FuWinship Cancer Institute of Emory University.
Fadlo R KhuriDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Wei ZhouDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Adam I MarcusDepartment of Hematology and Medical Oncology, Emory University School of Medicine.
Emory University · USCancer Institute (WIA) · INPurdue University West Lafayette · USWinship Cancer Institute
Funding
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MTargeting Microtubules and HDAC6 in NSCLCP01CA116676 · NCI · EMORY UNIVERSITY · PI KHURI, FADLO RAJA · 2006 to 2012
$8.0MENNCF - Viral Vector CoreP30NS055077 · NINDS · EMORY UNIVERSITY · PI LEVEY, ALLAN I · 2008 to 2018
$6.8MDeveloping a pharmacologic approach to treat LKB1 mutant NSCLC patientsR01CA194027 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.5MDefining Early Escape Strategies in LKB1 Mutant Lung Cancer S1R01CA201340 · NCI · EMORY UNIVERSITY · PI GILBERT-ROSS, MELISSA, MARCUS, ADAM I. · 2016 to 2020
$2.0MPro-Oncogenic Role of LKB1 in NSCLCR01CA140571 · NCI · EMORY UNIVERSITY · PI ZHOU, WEI · 2011 to 2015
$1.6MControl of lung cancer invasion and metastasis by vimentinR01CA142858 · NCI · EMORY UNIVERSITY · PI MARCUS, ADAM I. · 2011 to 2015
$1.6MIdentification and Therapeutic Application of miRNA-Drivers in Lung CancerR00CA178091 · NCI · PURDUE UNIVERSITY · PI KASINSKI, ANDREA L · 2014 to 2016
$734kDefining an LKB1-regulated motility switch in cancer cell invasion and metastasisF31CA180511 · NCI · EMORY UNIVERSITY · PI KONEN, JESSICA · 2014 to 2016
$118kNCI NIH HHS F31 CA180511NCI NIH HHS P01 CA116676NCI NIH HHS P30 CA138292NCI NIH HHS R00 CA178091NCI NIH HHS R01 CA140571NCI NIH HHS R01 CA142858NCI NIH HHS R01 CA194027NCI NIH HHS R01 CA201340NINDS NIH HHS P30 NS055077
Abstract
Loss of LKB1 activity is prevalent in
Indexed as
MutationSignal TransductionAdenocarcinomaAMP-Activated Protein Kinase KinasesAnimalsEnzyme ActivationFocal Adhesion Protein-Tyrosine KinasesHumansLung NeoplasmsMiceProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)AMP-Activated Protein Kinase KinasesFocal Adhesion Protein-Tyrosine KinasesKRAS protein, humanProtein Kinase InhibitorsProtein Serine-Threonine KinasesProto-Oncogene Proteins p21(ras)STK11 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.